Adaptimmune to Present Two Trials in Progress Posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
PHILADELPHIA and OXFORD, U.K., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it will present two trials in progress posters at the 2017 SITC annual meeting November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland, United States.
In addition, Adaptimmune will have a corporate exhibition booth (#718), and the company will also be hosting a dinner for investors on November 10th with representatives from Adaptimmune’s leadership team and key opinion leader Dr. David S. Hong from The University of Texas MD Anderson Cancer Center. Please reach out to Adaptimmune Investor Relations (email@example.com) for more information on attending the dinner.
The trials in progress posters will summarize the study designs for Adaptimmune’s ongoing MAGE‑A4 multi‑tumor study in urothelial (“bladder”), melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, and gastric cancers; and, the combination study with NY-ESO and NY‑ESO and KEYTRUDA® (pembrolizumab) in multiple myeloma Details are below.
Trials in Progress Posters:
Title: Study Design: Phase 1 dose escalation, multi-tumor study to assess safety, tolerability and antitumor activity of genetically engineered MAGE-A4 SPEAR T-cells in HLA-A2+ subjects with MAGE-A4+ tumors
- Poster Number: P247
- Session Time: November 10, 2017 from 12:30 PM to 2:00 PM (lunch) and 6:30 PM to 8:00 PM (reception)
- Location: Prince George’s Exhibition Hall DE
Title: Study Design: An Open-label Randomized Pilot Study of NY-ESO-1 SPEAR T-cells Alone or in Combination with Pembrolizumab in HLA-A2+ Subjects with Relapsed and Refractory Multiple Myeloma (NCT03168438)
- Poster Number: P248
- Session Time: November 11, 2017 from 12:30 PM to 2:00 PM (lunch) and 6:30 PM to 8:00 (reception)
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune is currently conducting clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP across several solid tumor indications. GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) exercised its option to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program in September 2017. Transition of this program to GSK is ongoing. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 2, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contacts Investor Relations
Juli P. Miller, Ph.D.
T: (215) 825-9310
T: +44 (0)1235 430036
Cell: +44 (0)7710 304249
Released November 3, 2017